Agreement with Xeda International

RNS Number : 9858X

Eden Research plc

24 February 2012

 



24 February 2012

GB0001646941/GBP/PLUS-exn

EDEN RESEARCH PLC

("Eden" or the "Company")

Agreement with Xeda International

Eden Research plc, the agrochemical and encapsulation development company, is pleased to announce that it has signed a Data Access and Royalty Agreement with Xeda International SA ("Xeda") of France.

The agreement enables Xeda to have full access to Eden's dossiers on both Geraniol and Thymol, two of the active terpene ingredients used in Eden products. In return for the access to the Geraniol data, Eden will receive full access to Xeda's Clove Oil data, and thereby be able to include the Clove Oil in future products. Importantly, Xeda's Clove Oil has already been included in the European Food Safety Authority's ("EFSA") Annex I, the list of substances approved by the EFSA for use in pesticidal products.

In return for access to its Thymol data, Eden will receive royalty payments on sales of Xeda's products which include this active ingredient.

Xeda is based in France and is one of the leaders in the treatment of fruit and vegetables, post-harvest.

Sir Ben Gill, Chairman of Eden, said, "We're very pleased to have reached this agreement with Xeda, a leader in the treatment of post-harvest produce. Access to the already approved Clove Oil data will broaden our own product offering whilst the agreement to share our Thymol dossier provides Eden with a further potential revenue stream."

The Directors of Eden are responsible for the contents of this announcement.

Enquiries:

Eden Research plc                                                                                                           01993 862761

Clive Newitt, Managing Director                                                                                             

Zeus Capital Limited                                                                                                      0161 831 1512

Ross Andrews, Brian Stockbridge

Threadneedle Communications                                                                               020 7653 9850

Josh Royston, Beth Harris

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com  

 

END

 

 

CNTTJMMTMBITBBT